• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
QLGN

QLGN

Qualigen Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD3.21

+0.17 (+5.59%)

Company Profile

CEO

Kevin A. Richardson II

IPO Date

2015-06-23

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$2.98

Prev. Close

$3.04

Day Low

$2.86

Day High

$3.34

52W Low

$1.61

52W High

$8.81

Market Cap

$0.01B

Volume

0.37M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

24.8%

Avg Negative

11.6%

Avg Neutral

63.6%

News Feed

Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19

GlobeNewsWire·7/14/2021·↑ positive

Qualigen Therapeutics, Inc. to Present at the LD Micro Invitational XI Conference

GlobeNewsWire·6/2/2021·↑ positive

Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer

GlobeNewsWire·5/19/2021·↑ positive

Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewsWire·5/14/2021·↓ negative

Qualigen Therapeutics Plans to Combat COVID-19 Variants

Benzinga·4/19/2021·↓ negative

Why Is Qualigen Stock Trading Lower Today?

Benzinga·4/12/2021·↓ negative

Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position

GlobeNewsWire·3/9/2021·↑ positive

Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference

GlobeNewsWire·3/8/2021·↑ positive

Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL

GlobeNewsWire·3/1/2021·↑ positive

Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering

PRNewsWire·12/18/2020·↑ positive